Bryan K Sorensen

USPTO Granted Patents = 40 (Patent Applications = 10)

CIPO Patents = 4 (Patent Applications = 7)

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 8.9

ph-index = 11

Forward Citations = 317(Granted Patents)

Location History:

Waukegan, IL (US) (1997 - 2008)
Antioch, IL (US) (2007 - 2018)

Company Filing History:

21 out of 4,177

Abbott Laboratories Corporation

University of Pittsburgh

patents

4. 1 out of 832,680

Other

patents

Years Active: 1997-2018

Loading Chart...

40 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10093624 - NAMPT and ROCK inhibitors (2018-10-09),

2. 9758511 - NAMPT inhibitors (2017-09-12),

3. 9464072 - Treatment of central nervous system disorders (2016-10-11),

4. 9302989 - NAMPT and rock inhibitors (2016-04-05),

5. 9296723 - NAMPT inhibitors (2016-03-29),

6. 9290444 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme (2016-03-22),

7. 9193723 - NAMPT inhibitors (2015-11-24),

8. 9187472 - NAMPT inhibitors (2015-11-17),

9. 9133145 - Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme (2015-09-15),

10. 9051315 - Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition (2015-06-09),

11. 8993632 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme (2015-03-31),

12. 8975398 - NAMPT inhibitors (2015-03-10),

13. 8940902 - Treatment of central nervous system disorders (2015-01-27),

14. 8716345 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme (2014-05-06),

15. 8691810 - Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases (2014-04-08),

Title: Bryan K. Sorensen – Innovator in Biochemical Patents

Introduction

Bryan K. Sorensen, based in Antioch, IL, is a notable inventor with an impressive portfolio of 40 patents. His work primarily focuses on pharmaceutical innovations, specifically in the development of compounds that target critical biochemical pathways related to disease treatment.

Latest Patents

Among his most recent contributions to the field are patents related to NAMPT and ROCK inhibitors. These patents disclose innovative isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds that inhibit the activity of NAMPT. Additionally, he has developed similar compounds aimed at ROCK inhibition. These inventions include compositions that incorporate these compounds and outline methods for treating diseases where NAMPT and ROCK are expressed.

Career Highlights

Bryan's career has been marked by significant contributions while working at prominent companies in the pharmaceutical industry, including Abbott Laboratories Corporation and AbbVie Inc. His expertise has allowed him to make substantial advancements in drug development and biochemistry.

Collaborations

Throughout his career, Bryan has collaborated with notable professionals such as Martin Winn and James T. Link. These partnerships have enhanced the innovation process and contributed to the successful development of his patented technologies.

Conclusion

With a solid foundation in biochemistry and a proven record of patent development, Bryan K. Sorensen continues to be a key player in the field of pharmaceutical innovations. His work, especially in the area of enzyme inhibitors, is paving the way for new therapeutic approaches to treating significant health conditions.

This text is generated by artificial intelligence and may not be accurate.